News
GOVX
1.420
-3.40%
-0.050
Weekly Report: what happened at GOVX last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at GOVX last week (0408-0412)?
Weekly Report · 04/15 11:28
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
Benzinga · 04/11 14:09
Weekly Report: what happened at GOVX last week (0401-0405)?
Weekly Report · 04/08 11:33
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. Candel Therapeutic shares moved upwards by 25.93% during the session. The company's market cap stands at $236.5 million.
Benzinga · 04/05 12:09
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress in Washington, DC. GeoVax Labs, Inc. Presented data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate. The company is developing immunotherapies and vaccines against cancers and infectious diseases.
Barchart · 04/04 11:30
Weekly Report: what happened at GOVX last week (0325-0329)?
Weekly Report · 04/01 11:30
GeoVax To Present Data On GEO-CM04S1, A Next Generation Covid-19 Vaccine, At The World Vaccine Congress
GeoVax's Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate. The vaccine is designed to induce both antibody and T cell responses to the SARS-CoV-2 variant of the virus. The presentation will be at the 24th Annual World Vaccine Congress in Washington, DC on April 4, 2024.
Benzinga · 03/28 13:06
Weekly Report: what happened at GOVX last week (0318-0322)?
Weekly Report · 03/25 11:33
Weekly Report: what happened at GOVX last week (0311-0315)?
Weekly Report · 03/18 11:31
Weekly Report: what happened at GOVX last week (0304-0308)?
Weekly Report · 03/11 11:27
Noble Financial Reaffirms Their Buy Rating on GeoVax Labs (GOVX)
GeoVax Labs has an analyst consensus of Moderate Buy, with a price target of $6.00. The company has a one-year high of $11.86 and a low of $2.15. Robert LeBoyer has maintained a Buy rating on the stock.
TipRanks · 03/07 13:15
Weekly Report: what happened at GOVX last week (0226-0301)?
Weekly Report · 03/04 11:31
GeoVax Labs files $100M mixed securities shelf
Seeking Alpha · 03/01 21:19
GeoVax Labs Inc Files For Mixed Shelf Of Up To $100M
Benzinga · 03/01 21:16
GeoVax Labs Inc reports results for the quarter ended in December - Earnings Summary
GeoVax Labs Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $13.60 per share. Reported revenue was zero; analysts expected zero. The average analyst rating on the shares is "buy" for the company.
Reuters · 03/01 17:20
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)
TipRanks · 03/01 13:10
GeoVax GAAP EPS of -$14.29 beats by $0.26
GeoVax Labs, Inc. (GOVX) FY GAAP EPS of -$14.29 beats by $0.26. GeoVax reported cash balances of $6.5 million on December 31, 2023, as compared to $27.6 million in 2022.
Seeking Alpha · 02/29 23:14
Geovax Labs: Q4 Earnings Insights
Geovax Labs reported its Q4 earnings on February 29. The company missed estimated earnings by -42.0%. The company reported revenue down $0 from the same period last year. Geovax labs is expected to report its earnings on Thursday, February 29 at 04:00 PM.
Benzinga · 02/29 21:10
Geovax Labs Q4 2023 GAAP EPS $(3.940) Misses $(2.780) Estimate
Benzinga · 02/29 21:08
More
Webull provides a variety of real-time GOVX stock news. You can receive the latest news about Geovax Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.